NASDAQ · MOLN
Healthcare · Biotechnology
$4.21
Up+$0.00 (+0.00%)
Updated Aug 16, 2026, 8:23 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 13 trading sessions · Daily adjusted prices
MOLN closed at $4.21 after 13 trading sessions, up 5.25% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $4.19 | $4.21 | $4.11 | $4.21 | 1.04K |
| Aug 13, 2026 | $4.21 | $4.21 | $4.21 | $4.21 | 1.32K |
| Aug 10, 2026 | $4.13 | $4.13 | $4.13 | $4.13 | 217.28 |
| Aug 6, 2026 | $4.05 | $4.0501 | $4.02 | $4.0501 | 722.55 |
| Aug 4, 2026 | $4.16 | $4.16 | $4.16 | $4.16 | 254 |
| Aug 3, 2026 | $4.25 | $4.25 | $4.07 | $4.12 | 6.09K |
| Jul 29, 2026 | $3.93 | $3.93 | $3.93 | $3.93 | 350 |
| Jul 28, 2026 | $3.925 | $3.925 | $3.8303 | $3.8303 | 436 |
| Jul 27, 2026 | $4.005 | $4.005 | $4.005 | $4.005 | 641.42 |
| Jul 24, 2026 | $3.92 | $3.92 | $3.89 | $3.89 | 1.05K |
| Jul 22, 2026 | $3.97 | $3.97 | $3.97 | $3.97 | 269.54 |
| Jul 21, 2026 | $4.11 | $4.11 | $4.11 | $4.11 | 760 |
| Jul 20, 2026 | $4.044 | $4.044 | $4.00 | $4.00 | 2.75K |
The latest Smart Investors Daily articles mentioning MOLN.
MOLN research
Company profile and research snapshot.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 6, 2026 | TD COWEN | Buy | — |
| Feb 2, 2026 | CLEAR STREET LLC | Buy | — |
| Feb 2, 2026 | TD COWEN | Buy | — |
| Feb 1, 2026 | CLEAR STREET LLC | Buy | — |
| Dec 15, 2025 | CLEAR STREET LLC | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 16, 2026
Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoingData update expected in 2027, with trial completion in 2028Trial-in-progress poster to be
Benzinga · Jul 15, 2026
Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacyPresentation outlines Radio-DARPins’ ability to match target and disease biology for
Benzinga · Jul 6, 2026
Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected
Benzinga · Jul 2, 2026
Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712Dosing ongoing in first patients, consecutively moving to subsequent dosing cyclesInitial data anticipated within the coming months,
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MOLN.
